- Home
- SEED vs CURX Comparison
SEED vs CURX Comparison
Compare SEED & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | CURX |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.5M |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SEED | CURX |
|---|---|---|
| Price | $0.93 | $4.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 106.8K | 20.0K |
| Earning Date | 05-21-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.21 |
| 52 Week High | $2.12 | $16.93 |
Technical Indicators
Market Signals| Indicator | SEED | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 56.11 |
| Support Level | $0.68 | $3.79 |
| Resistance Level | $1.08 | $5.29 |
| Average True Range (ATR) | 0.10 | 0.50 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 33.55 | 61.72 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.